Ranbaxy Laboratories rises on getting USFDA nod for Acetaminophen

16 Dec 2011 Evaluate

Ranbaxy Laboratories is currently trading at Rs 385.45, up by 1.50 points or 0.39% from its previous closing of Rs 383.95 on the BSE.

The scrip opened at Rs 386.00 and has touched a high and low of Rs 391.30 and Rs 385.00 respectively. So far 56877 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 611.75 on 04-Jan-2011 and a 52 week low of Rs 380.10 on 15-Dec-2011.

Last one week high and low of the scrip stood at Rs 420.05 and Rs 380.10 respectively. The current market cap of the company is Rs 16202.68 crore.

The promoters holding in the company stood at 63.75% while Institutions and Non-Institutions held 20.50% and 14.00% respectively. 

Ranbaxy Laboratories has received US Food and Drug Administration (USFDA) approval to sell its generic drug acetaminophen in the world’s largest drug market. Acetaminophen is used for relief of headaches and other minor aches and pains.

Recently, Ranbaxy Laboratories had managed to capture about 2.5% market share in the generic Lipitor segment during initial days of its launch in the US.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.